Cyrus V Desouza, MBBS

Professor

  • 3870 Citations
  • 23 h-Index
20012019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Cyrus V Desouza is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles
Type 2 Diabetes Mellitus Medicine & Life Sciences
Insulin Medicine & Life Sciences
pioglitazone Medicine & Life Sciences
Placebos Medicine & Life Sciences
Cardiovascular Diseases Medicine & Life Sciences
Type 1 Diabetes Mellitus Medicine & Life Sciences
Inflammation Medicine & Life Sciences
Obesity Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation

Saraswathi, V., Heineman, R., Alnouti, Y., Shivaswamy, V. & Desouza, C. V., Jan 1 2019, (Accepted/In press) In : Journal of Diabetes and Its Complications. 107494.

Research output: Contribution to journalArticle

Naproxen
Cyclooxygenase Inhibitors
Dyslipidemias
Adipose Tissue
Obesity

Altered motor dynamics in type 1 diabetes modulate behavioral performance

Embury, C. M., Heinrichs-Graham, E., Lord, G. H., Drincic, A. T., Desouza, C. V. & Wilson, T. W., 2019, In : NeuroImage: Clinical. 24, 101977.

Research output: Contribution to journalArticle

Open Access
Type 1 Diabetes Mellitus
Motor Cortex
Vascular Diseases
Comorbidity
Young Adult
105 Citations (Scopus)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

REWIND Investigators, Jul 13 2019, In : The Lancet. 394, 10193, p. 121-130 10 p.

Research output: Contribution to journalArticle

Type 2 Diabetes Mellitus
Randomized Controlled Trials
Placebos
Cardiovascular Diseases
Incidence
33 Citations (Scopus)

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

REWIND Investigators, Jul 13 2019, In : The Lancet. 394, 10193, p. 131-138 8 p.

Research output: Contribution to journalArticle

Type 2 Diabetes Mellitus
Randomized Controlled Trials
Placebos
Glomerular Filtration Rate
Kidney
10 Citations (Scopus)
Type 2 Diabetes Mellitus
Placebos
Kidney
Safety
Therapeutics